DNA binding proteins that associates with chromatin and has the ability to bend DNA. Binds preferentially single-stranded DNA. Involved in V(D)J recombination by acting as a cofactor of the RAG complex. Acts by stimulating cleavage and RAG protein binding at the 23 bp spacer of conserved recombination signal sequences (RSS). Heparin-binding protein that has a role in the extension of neurite-type cytoplasmic processes in developing cells. Component of the RAG complex composed of core components RAG1 and RAG2, and associated component HMGB1 or HMGB2. Belongs to the HMGB family. Note: This description may include information from UniProtKB.
Protein type: DNA repair, damage; Nuclear receptor co-regulator
Molecular Function: bubble DNA binding; C-X-C chemokine binding; chemoattractant activity; cytokine activity; damaged DNA binding; DNA bending activity; double-stranded DNA binding; double-stranded RNA binding; four-way junction DNA binding; lipopolysaccharide binding; lyase activity; phosphatidylserine binding; protein binding; protein kinase activator activity; RAGE receptor binding; single-stranded DNA binding; single-stranded RNA binding; transcription factor activity; transcription factor binding
Biological Process: activation of innate immune response; activation of protein kinase activity; apoptotic cell clearance; autophagy; base-excision repair; chromatin assembly; dendritic cell chemotaxis; DNA fragmentation during apoptosis; DNA geometric change; DNA ligation during DNA repair; DNA recombination; DNA topological change; elevation of cytosolic calcium ion concentration; endothelial cell proliferation; eye development; inflammatory response; inflammatory response to antigenic stimulus; innate immune response; lung development; macrophage activation during immune response; myeloid dendritic cell activation; negative regulation of blood vessel endothelial cell migration; negative regulation of CD4-positive, alpha beta T cell differentiation; negative regulation of interferon-gamma production; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcriptional preinitiation complex assembly; neurite development; plasmacytoid dendritic cell activation; positive chemotaxis; positive regulation of activated T cell proliferation; positive regulation of apoptosis; positive regulation of caspase activity; positive regulation of DNA binding; positive regulation of DNA ligation; positive regulation of glycogen catabolic process; positive regulation of interferon-alpha production; positive regulation of interferon-beta production; positive regulation of interleukin-1 beta secretion; positive regulation of interleukin-1 secretion; positive regulation of interleukin-10 production; positive regulation of interleukin-12 production; positive regulation of JNK cascade; positive regulation of MAPKKK cascade; positive regulation of mismatch repair; positive regulation of myeloid cell differentiation; positive regulation of toll-like receptor 2 signaling pathway; positive regulation of toll-like receptor 4 signaling pathway; positive regulation of toll-like receptor 9 signaling pathway; positive regulation of transcription from RNA polymerase II promoter; positive regulation of tumor necrosis factor production; regulation of autophagy; regulation of restriction endodeoxyribonuclease activity; regulation of T cell mediated immune response to tumor cell; regulation of tolerance induction; regulation of transcription from RNA polymerase II promoter; response to glucocorticoid stimulus; T-helper 1 cell differentiation; V(D)J recombination
Alt. Names/Synonyms: Amphoterin; DKFZp686A04236; high mobility group box 1; High mobility group protein 1; High mobility group protein B1; high-mobility group (nonhistone chromosomal) protein 1; high-mobility group box 1; HMG-1; HMG1; HMG3; HMGB1; SBP-1; Sulfoglucuronyl carbohydrate binding protein
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.